Royalty Report: Drugs, Therapeutic, Disease – Collection: 7362

License Grant

Pursuant to the Agreement, the Licensee has an option to acquire an exclusive, worldwide (excluding Japan) License of our Tcelna program for the treatment of MS.

License Property

The Licensor is a biopharmaceutical company developing a personalized immunotherapy with the potential to treat major illnesses, including multiple sclerosis (MS). This therapy is based on proprietary T-cell technology. MS is a chronic, often disabling disease that affects the central nervous system. MS attacks the covering surrounding nerve cells, or myelin sheaths, leading to loss of myelin (demyelination) and nerve damage.

Tcelna is a novel T-cell immunotherapy in Phase IIb clinical development for the treatment of patients with SPMS. It is also positioned to enter Phase III clinical development for the treatment of patients with relapsing remitting MS (RRMS), subject to the availability of sufficient resources. Tcelna is a personalized therapy that is specifically tailored to each patient's disease profile. Tcelna is manufactured using ImmPathTM, our proprietary methodd for the production of a patient-specific T-cell immunotherapy which encompasses the collection of blood from the MS patient, isolation of peripheral blood mononuclear cells, generation of an autologous pool of MRTCs raised against selected peptides from myelin basic protein (MBP), myelin oligodendrocyte glycoprotein (MOG) and proteolipid protein (PLP), and the return of these expanded, irradiated T-cells back to the patient.

License Grant

Licensee entered into an agreement with College for the exclusive worldwide license to a patient-specific, autologous T-cell immunotherapy for the treatment of MS, which is the initial T-cell technology on which Tcelna is based, including rights to certain patents held by the College.

License Property

Tcelna was based on our novel T-cell immunotherapy platform, ImmPath, which produces an autologous T-cell immunotherapy utilizing a patient’s own blood.

Field of Use

Tcelna® is a personalized T-cell immunotherapy in a Phase IIb clinical development program (the Abili-T trial) for the treatment of Secondary Progressive Multiple Sclerosis.

License Grant

The Licensee has an exclusive, worldwide license from the College to develop and commercialize three technology areas for MS, namely T-cell vaccination, peptides, and diagnostics. Under the License Agreement with the College, the licensee will have rights to a total of 7 patents (2 U.S. and 5 foreign) and 69 patent applications (6 U.S., 62 foreign, and 1 Patent Cooperation Treaty [PCT]). Our multiple sclerosis cell therapy, Tovaxin, is currently in Phase I/II studies.

License Property

Tovaxin consists of modified auto reactive T cells. Multiple sclerosis is a result of a person’s own T cells attacking the myelin sheath that coats the nerve cells of the central nervous system. These T cells, that attack a person’s own body, are referred to as auto reactive T cells. In our treatment the T cells are taken from the patient, modified and returned to the patient. The modified T cells cause an immune response directed at the auto reactive T cells in the patient’s body. This immune response reduces the level of auto reactive T cells and potentially allows the myelin sheath to be repaired. In addition, we are evaluating whether this technology will allow us to diagnose multiple sclerosis and determine the severity of the disease through an analysis of the level of auto reactive T cells in a patient’s blood.

License Grant

This License Agreement provides for worldwide distribution rights for so long as there are patent rights and the parties continue their corporate existence.

License Property

BOW 304 is a drug being developed for the treatment of Multiple Sclerosis and related neurological symptoms.  The product is to be developed through a joint development and marketing agreement with a British based research and development partnership.

Chronic progressive multiple sclerosis (MS) is a severely disabling demyelinating disease in which autoimmune processes seem to have a major role in the destruction of brain and nerve tissue. Treatment options are limited although beta-interferon has been widely reported to have some beneficial effect in MS. It is assumed that beta interferon has its action on the cells of the immune system that are attacking the patient’s nerve tissue.

Field of Use

The rights granted relate to neurological symptoms.

License Grant

The Licensee was granted an exclusive, worldwide License from the College of Medicine, the Licensor, to patent applications claiming rights to the treatment of multiple sclerosis using attenuated modified T-cells and to the use of the T-cell technology as a diagnostic.

Field of Use

The Licensee is a biopharmaceutical company developing autologous cellular therapies to treat several major illnesses, including multiple sclerosis (MS), rheumatoid arthritis (RA), diabetes, and cardiovascular disease. These therapies are based on the Company’s proprietary T-cell and adult stem cell technology.

License Grant

Licensor hereby grants to Canadian Licensee the exclusive worldwide right and license under the Patent Rights to use, manufacture, have manufactured, import, offer for sale and sell the Licensed Products for use in the Field.

License Property

The Licensor is a biopharmaceutical company that develops drug therapies for the treatment of inflammatory diseases.

USA Patents
6,039,947 – Peptides derived from immunodominant epitopes of myelin basic protein
5,858,980 – Peptide fragments of myelin basic protein
6,077,509 – Peptide fragments of myelin basic protein
6,036,957 – Suppression of T-cell proliferation using peptide fragments of myelin basic protein

Field of Use

Field shall mean the administration of native myelin basic protein (MBP) peptides by injection to non-mucosal sites for the treatment of multiple sclerosis.

License Grant

Licensor grants to the Swiss Licensee an exclusive license with the right to sublicense, under the Licensor Technology to manufacture, have manufactured, develop, use, sell, import, and otherwise distribute Collaboration Products for use within the Licensee Territory and North America. Without limiting the foregoing, it is understood that the license granted hereunder shall extend to the use of Collaboration Products for multiple sclerosis as well as any other indication outside the Field.

License Property

Licensor Technology shall mean Licensor Patents and Licensor Know-How.  The Licensor discovers, develops and commercializes innovative and life-changing pharmaceuticals, in diseases with high unmet medical needs, through its novel research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders.

Field of Use

The Parties desire to collaborate on the development and commercialization of altered peptide ligand compounds for the diagnosis, treatment and/or prevention of multiple sclerosis ('MS') in humans

Field shall mean the development, manufacture, use and sale of altered peptide ligand (APL) compounds for diagnosis, treatment and/or prevention of multiple sclerosis (MS) the mechanism of action of which is to modulate the immune response to neuro antigens, which neuro antigens include without limitation myelinoasic protein (which constitutes approximately 30% of the protein in myelin) as well as myelin associated glycoprotein (MAG), myelin oligodendroglia glycoprotein (MOG), transaldolase, 23 cyclic nuclcotide 3, phosphodieseterases (CNP), alpha/beta crystallin and proteolipid protein {PLP).

License Grant

The Licensor grants to the Licensee the exclusive, worldwide right to conduct various technical, preclinical, marketing, patent, and other studies on products in the field of vaccines for the diagnosis or treatment of diseases.

License Property

Through our majority owned subsidiary Solovax we have an exclusive option agreement, as amended, with the University to license U.S. Patent Application serial nos. 09/156509 and 10/773356 and its foreign equivalents entitled “T-Cell Vaccination for the Treatment of Multiple Sclerosis.”